Lipodystrophy Syndrome (LS) Market Insights, Epidemiology and Market Forecast - 2028

Publisher Name :
Date: 15-Apr-2019
No. of pages: 120
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's Lipodystrophy Syndrome (LS)- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Lipodystrophy Syndrome (LS) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Lipodystrophy Syndrome (LS) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

- The United States

- EU5 (Germany, France, Italy, Spain and the United Kingdom)

- Japan

Study Period: 2017-2028

Lipodystrophy Syndrome (LS) - Disease Understanding and Treatment Algorithm

Lipodystrophies are a group of rare disorders of diverse etiology which are characterized by variable loss of body fat. The loss of body fat may affect nearly the entire body (generalized), only certain body regions (partial) or small areas under the skin (localized). Depending upon the severity and extent of body fat loss, patients may be predisposed to metabolic complications associated with insulin resistance. These metabolic complications include early onset of diabetes mellitus, hypertriglyceridemia and hepatic steatosis.

There are many different types of lipodystrophy. It can be acquired, or genetic (inherited). The inherited form may be present at birth or develop during childhood (congenital). It may result in fat loss in only one area of the body or throughout the body (generalized).

Generalized lipodystrophy refers to the situation in which the fat tissue throughout the body is affected (sometimes mistaken for weight or fat gain).

Partial, or localized, lipodystrophy affects only one area of the body and is not associated with abnormal health generally.

The DelveInsight Lipodystrophy Syndrome (LS) market report gives the thorough understanding of the Lipodystrophy Syndrome (LS) by including details such as disease definition, type, clinical manifestations, risk factors, pathogenesis, and diagnostic trends, prognosis and prevention. It also provides treatment algorithms and treatment guidelines for Lipodystrophy Syndrome (LS) in the US, Europe, and Japan.

Lipodystrophy Syndrome (LS) Epidemiology

The Lipodystrophy Syndrome (LS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Total Prevalent Population of Lipodystrophy Syndrome (LS), Type Specific Prevalent of Lipodystrophy Syndrome (LS), Diagnosed and Treatable Cases of Lipodystrophy Syndrome (LS)] scenario of Lipodystrophy Syndrome (LS) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017-2028.

As per Elaine Chiquette et. Al., the estimated prevalence of diagnosed Lipodystrophy Syndrome (LS) was 3.07 cases/million (95% confidence interval [CI], 2.30-4.02), 0.23 cases/million (95% CI, 0.06-0.59) and 2.84 cases/million (95% CI, 2.10-3.75) for generalized lipodystrophy (GL) and partial lipodystrophy (PL), respectively.

According to Orphanet registry, Primary lipodystrophies prevalence has been estimated at less than 1 case in 100 000.

DelveInsight estimates that the prevalent population of Lipodystrophy Syndrome (LS) will significantly change during the study period [2017-2028].

Lipodystrophy Syndrome (LS) Drug Chapters

This segment of the Lipodystrophy Syndrome (LS) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Current therapies prevent or ameliorate the comorbidities of Lipodystrophy Syndrome (LS). At present, Myalept (Bristol-Myers Squibb) (recombinant human methionyl leptin) is the only drug approved specifically for lipodystrophy. It is approved in the United States as an adjunct to diet for treatment of metabolic complications in patients with generalized lipodystrophy.

Key players such as Ionis Pharmaceuticals, Zydus Cadila and many others are involved in developing therapies for Lipodystrophy Syndrome (LS). Expected launch of emerging therapies such as Volanesorsen (Ionis Pharmaceuticals), Lipaglyn (Zydus Cadila) and some other are expected to change the treatment landscape of Lipodystrophy Syndrome (LS) in upcoming years.

Lipodystrophy Syndrome (LS) Market Outlook

The Lipodystrophy Syndrome (LS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The market of Lipodystrophy Syndrome (LS) in 7MM is expected to change from the study period 2017-2028.

Lipodystrophy Syndrome (LS) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Lipodystrophy Syndrome (LS) Report Insights

- Patient Population

- Therapeutic Approaches

- Pipeline Analysis

- Market Size and Trends

- Market Opportunities

- Impact of upcoming Therapies

Lipodystrophy Syndrome (LS) Report Key Strengths

- 10 Years Forecast

- 7MM Coverage

- Epidemiology Segmentation

- Key Cross Competition

- Highly Analyzed Market

- Drugs Uptake

Lipodystrophy Syndrome (LS) Report Assessment

- Current Treatment Practices

- Unmet Needs

- Pipeline Product Profiles

- Market Attractiveness

- Market Drivers and Barriers

Key Benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Lipodystrophy Syndrome (LS) market

Organize sales and marketing efforts by identifying the best opportunities for Lipodystrophy Syndrome (LS) market

To understand the future market competition in the Lipodystrophy Syndrome (LS) market.

Lipodystrophy Syndrome (LS) Market Insights, Epidemiology and Market Forecast - 2028

Table of Contents

1. Report Introduction
2. Lipodystrophy Syndrome (LS) Market Overview at a Glance
2.1. 7 Major Market Size of Lipodystrophy Syndrome (LS) in 2018
2.2. 7 Major Market Size of Lipodystrophy Syndrome (LS) in 2028
3. Disease Background and Overview: Lipodystrophy Syndrome (LS)
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. 7MM Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
4.2. 7MM Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
4.3. 7MM Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2028)
5. Lipodystrophy Syndrome (LS): Country- Wise Epidemiology
5.1. United States
5.2. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.3. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.4. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5. EU-5
5.5.1. Assumptions and Rationale
5.5.2. Germany
5.5.2.1. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5.2.2. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5.2.3. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5.3. France
5.5.3.1. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5.3.2. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5.3.3. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5.4. Italy
5.5.4.1. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5.4.2. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5.4.3. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5.5. Spain
5.5.5.1. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5.5.2. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5.5.3. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5.6. United Kingdom
5.5.6.1. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5.6.2. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.5.6.3. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.6. Japan
5.6.1. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.6.2. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2028)
5.6.3. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2028)
6. Treatments & Medical Practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Marketed drug
7.1.1. Myalept: Bristol-Myers Squibb
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Advantages & Disadvantages
7.1.5. Safety and Efficacy
7.1.6. Product Profile
To be continued in the report…
8. Emerging Therapies
8.1. Key Cross Competition
8.1.1. Volanesorsen: Ionis Pharmaceuticals
8.1.1.1. Regulatory Milestones
8.1.1.2. Clinical Development
8.1.1.3. Product Profile
8.1.1.4. Clinical Pipeline Activity
8.1.1.4.1. Ongoing Trials Information
8.1.1.4.2. Clinical Trial by Phase
8.1.2. Lipaglyn: Zydus Cadila
8.1.2.1. Regulatory Milestones
8.1.2.2. Clinical Development
8.1.2.3. Product Profile
8.1.2.4. Clinical Pipeline Activity
8.1.2.4.1. Ongoing Trials Information
8.1.2.4.2. Clinical Trial by Phase
To be continued in report…
9. Lipodystrophy Syndrome (LS) Market Size
9.1. Key Findings
9.2. Total 7MM Lipodystrophy Syndrome (LS) Market Analysis
9.2.1. Overview of Total Lipodystrophy Syndrome (LS) Market
9.2.2. Market size of Lipodystrophy Syndrome (LS) Market by 7MM (2016-2028)
10. 7MM: Country-Wise Market Analysis
10.1. United States Market Size
10.1.1. Total Market Size of Lipodystrophy Syndrome (LS)
10.1.2. Market Size of Lipodystrophy Syndrome (LS) by Therapies
10.2. Germany Market Size
10.2.1. Total Market Size of Lipodystrophy Syndrome (LS)
10.2.2. Market Size of Lipodystrophy Syndrome (LS) by Therapies
10.3. France Market Size
10.3.1. Total Market Size of Lipodystrophy Syndrome (LS)
10.3.2. Market Size of Lipodystrophy Syndrome (LS) by Therapies
10.4. United Kingdom Market Size
10.4.1. Total Market Size of Lipodystrophy Syndrome (LS)
10.4.2. Market Size of Lipodystrophy Syndrome (LS) by Therapies
10.5. Spain Market Size
10.5.1. Total Market Size of Lipodystrophy Syndrome (LS)
10.5.2. Market Size of Lipodystrophy Syndrome (LS) by Therapies
10.6. Italy Market Size
10.6.1. Total Market Size of Lipodystrophy Syndrome (LS)
10.6.2. Market Size of Lipodystrophy Syndrome (LS) by Therapies
10.7. Japan Market Size
10.7.1. Total Market Size of Lipodystrophy Syndrome (LS)
10.7.2. Market Size of Lipodystrophy Syndrome (LS) by Therapies
11. Market Drivers
12. Market Barriers
13. Report Methodology
13.1. Sources Used
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight

List of Tables

Table 1 Prevalent Cases of Lipodystrophy Syndrome (LS) in 7MM (2017-2028)
Table 2 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in 7MM (2017-2028)
Table 3 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in 7MM (2017-2028)
Table 4 Prevalent Cases of Lipodystrophy Syndrome (LS) in the US (2017-2028)
Table 5 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in the US (2017-2028)
Table 6 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in the US (2017-2028)
Table 7 Prevalent Cases of Lipodystrophy Syndrome (LS) in the Germany (2017-2028)
Table 8 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in the Germany (2017-2028)
Table 9 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in the Germany (2017-2028)
Table 10 Prevalent Cases of Lipodystrophy Syndrome (LS) in the Italy (2017-2028)
Table 11 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in the Italy (2017-2028)
Table 12 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in the Italy (2017-2028)
Table 13 Prevalent Cases of Lipodystrophy Syndrome (LS) in the Spain (2017-2028)
Table 14 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in the Spain (2017-2028)
Table 15 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in the Spain (2017-2028)
Table 16 Prevalent Cases of Lipodystrophy Syndrome (LS) in the France (2017-2028)
Table 17 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in the France (2017-2028)
Table 18 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in the France (2017-2028)
Table 19 Prevalent Cases of Lipodystrophy Syndrome (LS) in the UK (2017-2028)
Table 20 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in the UK (2017-2028)
Table 21 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in the UK (2017-2028)
Table 22 Prevalent Cases of Lipodystrophy Syndrome (LS) in the Japan (2017-2028)
Table 23 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in the Japan (2017-2028)
Table 24 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in the Japan (2017-2028)
Table 25 Volanesorsen, Clinical Trials by Recruitment status, 2018
Table 26 Volanesorsen, Clinical Trials by Zone, 2018
Table 27 Lipaglyn, Clinical Trials by Recruitment status, 2018
Table 28 Lipaglyn, Clinical Trials by Zone, 2018
Table 29 Total 7 Major Market Size in USD, Million (2017-2028)
Table 30 Region wise Market Size) in USD, Million (2017-2028)
Table 31 7MM-Market Size by Therapy in USD, Million (2017-2028)
Table 32 United States Market Size in USD, Million (2017-2028)
Table 33 United States Market Size by Therapy in USD, Million (2017-2028)
Table 34 Germany Market Size in USD, Million (2017-2028)
Table 35 Germany Market Size by Therapy in USD, Million (2017-2028)
Table 36 France Market Size in USD, Million (2017-2028)
Table 37 France Market Size by Therapy in USD, Million (2017-2028)
Table 38 United Kingdom Market Size in USD, Million (2017-2028)
Table 39 United Kingdom Market Size by Therapy in USD, Million (2017-2028)
Table 40 Spain Market Size in USD, Million (2017-2028)
Table 41 Spain Market Size by Therapy in USD, Million (2017-2028)
Table 42 Italy Market Size in USD, Million (2017-2028)
Table 43 Italy Market Size by Therapy in USD, Million (2017-2028)
Table 44 Japan Market Size in USD, Million (2017-2028)
Table 45 Japan Market Size by Therapy in USD, Million (2017-2028)

List of Figures

Figure 1 Prevalent Cases of Lipodystrophy Syndrome (LS) in 7MM (2017-2028)
Figure 2 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in 7MM (2017-2028)
Figure 3 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in 7MM (2017-2028)
Figure 4 Prevalent Cases of Lipodystrophy Syndrome (LS) in the US (2017-2028)
Figure 5 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in the US (2017-2028)
Figure 6 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in the US (2017-2028)
Figure 7 Prevalent Cases of Lipodystrophy Syndrome (LS) in the Germany (2017-2028)
Figure 8 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in the Germany (2017-2028)
Figure 9 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in the Germany (2017-2028)
Figure 10 Prevalent Cases of Lipodystrophy Syndrome (LS) in the Italy (2017-2028)
Figure 11 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in the Italy (2017-2028)
Figure 12 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in the Italy (2017-2028)
Figure 13 Prevalent Cases of Lipodystrophy Syndrome (LS) in the Spain (2017-2028)
Figure 14 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in the Spain (2017-2028)
Figure 15 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in the Spain (2017-2028)
Figure 16 Prevalent Cases of Lipodystrophy Syndrome (LS) in the France (2017-2028)
Figure 17 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in the France (2017-2028)
Figure 18 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in the France (2017-2028)
Figure 19 Prevalent Cases of Lipodystrophy Syndrome (LS) in the UK (2017-2028)
Figure 20 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in the UK (2017-2028)
Figure 21 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in the UK (2017-2028)
Figure 22 Prevalent Cases of Lipodystrophy Syndrome (LS) in the Japan (2017-2028)
Figure 23 Type specific Prevalent cases of Lipodystrophy Syndrome (LS) in the Japan (2017-2028)
Figure 24 Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) in the Japan (2017-2028)
Figure 25 Volanesorsen, Clinical Trials by Recruitment status, 2018
Figure 26 Volanesorsen, Clinical Trials by Zone, 2018
Figure 27 Lipaglyn, Clinical Trials by Recruitment status, 2018
Figure 28 Lipaglyn, Clinical Trials by Zone, 2018
Figure 29 Total 7 Major Market Size in USD, Million (2017-2028)
Figure 30 Region wise Market Size) in USD, Million (2017-2028)
Figure 31 7MM-Market Size by Therapy in USD, Million (2017-2028)
Figure 32 United States Market Size in USD, Million (2017-2028)
Figure 33 United States Market Size by Therapy in USD, Million (2017-2028)
Figure 34 Germany Market Size in USD, Million (2017-2028)
Figure 35 Germany Market Size by Therapy in USD, Million (2017-2028)
Figure 36 France Market Size in USD, Million (2017-2028)
Figure 37 France Market Size by Therapy in USD, Million (2017-2028)
Figure 38 United Kingdom Market Size in USD, Million (2017-2028)
Figure 39 United Kingdom Market Size by Therapy in USD, Million (2017-2028)
Figure 40 Spain Market Size in USD, Million (2017-2028)
Figure 41 Spain Market Size by Therapy in USD, Million (2017-2028)
Figure 42 Italy Market Size in USD, Million (2017-2028)
Figure 43 Italy Market Size by Therapy in USD, Million (2017-2028)
Figure 44 Japan Market Size in USD, Million (2017-2028)
Figure 45 Japan Market Size by Therapy in USD, Million (2017-2028)
  • Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H1 2019
    Published: 23-Apr-2019        Price: US 3500 Onwards        Pages: 48
    Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H1 2019 Summary Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Mitogen-activated protein kinase 8 is an enzyme encoded by the MAPK8 gene. It is invo......
  • Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Pipeline Review, H1 2019
    Published: 23-Apr-2019        Price: US 3500 Onwards        Pages: 140
    Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Pipeline Review, H1 2019 Summary According to the recently published report 'Angiopoietin 1 Receptor - Pipeline Review, H1 2019'; Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tu......
  • 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H1 2019
    Published: 23-Apr-2019        Price: US 3500 Onwards        Pages: 73
    5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H1 2019 Summary 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report 5' Nucleotidase - Pipeline Review, H1 2019, outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotid......
  • Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H1 2019
    Published: 23-Apr-2019        Price: US 3500 Onwards        Pages: 75
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H1 2019 Summary Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Integrin beta-3 (?3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin,......
  • Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2019
    Published: 23-Apr-2019        Price: US 3500 Onwards        Pages: 85
    Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2019 Summary According to the recently published report 'Smoothened Homolog - Pipeline Review, H1 2019'; Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. Smoothened Homolog (Protein Gx or SMO) - Smoothened homolog (SMO) is a G protein-coupled re......
  • Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Pipeline Review, H1 2019
    Published: 23-Apr-2019        Price: US 3500 Onwards        Pages: 59
    Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Pipeline Review, H1 2019 Summary Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) pipeline ......
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Pipeline Review, H1 2019
    Published: 23-Apr-2019        Price: US 3500 Onwards        Pages: 38
    Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Pipeline Review, H1 2019 Summary Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Respiratory syncytial virus G protein is a protein produced by respiratory syncytial virus. It attaches the virion to the host cell membrane by interacting with heparan sulfate. It interacts with host CX3CR1, the receptor for the CX3C chemokine fractalkine, to modulate the immune response and facilitate in......
  • Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H1 2019
    Published: 23-Apr-2019        Price: US 3500 Onwards        Pages: 78
    Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H1 2019 Summary According to the recently published report 'Survival Motor Neuron Protein - Pipeline Review, H1 2019'; Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) pipeline Target constitutes close to 18 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. ......
  • Global DHA Oil Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 23-Apr-2019        Price: US 3480 Onwards        Pages: 138
    Scope of the Report: The worldwide market for DHA Oil is expected to grow at a CAGR of roughly over the next five years, will reach million US$ in 2024, from million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the DHA Oil in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Mar......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs